<?xml version="1.0" encoding="UTF-8"?> <!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd"> <ArticleSet> <Article> <Journal> <PublisherName>jmedicalcasereports</PublisherName> <JournalTitle>Frontiers in Medical Case Reports</JournalTitle> <PISSN>I</PISSN> <EISSN>S</EISSN> <Volume-Issue>Volume 3; Issue 6</Volume-Issue> <PartNumber/> <IssueTopic>Multidisciplinary</IssueTopic> <IssueLanguage>English</IssueLanguage> <Season>(Nov-Dec, 2022)</Season> <SpecialIssue>N</SpecialIssue> <SupplementaryIssue>N</SupplementaryIssue> <IssueOA>Y</IssueOA> <PubDate> <Year>-0001</Year> <Month>11</Month> <Day>30</Day> </PubDate> <ArticleType>Medical Case Reports</ArticleType> <ArticleTitle>Variants of Coronavirus and Cardiovascular Diseases</ArticleTitle> <SubTitle/> <ArticleLanguage>English</ArticleLanguage> <ArticleOA>Y</ArticleOA> <FirstPage>1</FirstPage> <LastPage>11</LastPage> <AuthorList> <Author> <FirstName>Mahintaj</FirstName> <LastName>Dara</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>N</CorrespondingAuthor> <ORCID/> <FirstName>Mahsa</FirstName> <LastName>Saffar</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> <FirstName>Mehdi</FirstName> <LastName>Dianatpour</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> <FirstName>Nader</FirstName> <LastName>Tanideh</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> <FirstName>Negar</FirstName> <LastName>Azarpira</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> <FirstName>Mahdieh</FirstName> <LastName>Talebzadeh</LastName> <AuthorLanguage>English</AuthorLanguage> <Affiliation/> <CorrespondingAuthor>Y</CorrespondingAuthor> <ORCID/> </Author> </AuthorList> <DOI/> <Abstract>Context: Coronavirus disease 2019 (COVID-19) is a viral infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) that spread around the world rapidly and has become a pandemic and a major global concern. SARS-CoV-2 is an enveloped virus with a positive-strand RNA genome that encodes structural and nonstructural viral proteins. Among the structural proteins, spike surface glycoprotein or S protein is necessary for the infection of host cells. Mutations in the S protein can cause dangerous variants of coronaviruses with higher transmission rates that are not easily detectable by routine diagnostic tests and are treatment resistant, leading to a more severe illness and a higher mortality rate. This review aimed to present a comprehensive evaluation of the latest studies on S protein mutations, coronavirus variants, and their relationship with the type, rate, and severity of the cardiovascular disease. Evidence Acquisition: Researchers search GISAID, PubMed/Medline, Google Scholar, Web of Science, Wiley Online Library, and Research Gate for the internationally valid investigation that includes original, reviews, letters or commentaries, or any other published data. Results: Since the outbreak of the COVID-19 pandemic disease, more than 30 mutations in the S protein. The mutations in the S protein increase the affinity and strength of its binding to the host cell receptor. Although the main host of the virus is the respiratory system, Cardiovascular damage, especially myocardial injury, has a significant share in patients with covid-19, which is of great importance due to the increase in the mortality rate. Conclusion: The mutations in the S protein increase the affinity and strength of its binding to the ACE2 receptor. Therefore, the signaling pathways associated with cardiovascular damage and inflammation are activated quickly, causing cardiovascular manifestation, severe forms of the disease, and death as a result of infection with concerning variants of SARS-CoV-2.</Abstract> <AbstractLanguage>English</AbstractLanguage> <Keywords>COVID-19,S Protein,Cardiovascular Diseases,SARS-Cov-2 Variants</Keywords> <URLs> <Abstract>https://www.jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=14144&title=Variants of Coronavirus and Cardiovascular Diseases</Abstract> </URLs> <References> <ReferencesarticleTitle>References</ReferencesarticleTitle> <ReferencesfirstPage>16</ReferencesfirstPage> <ReferenceslastPage>19</ReferenceslastPage> <References>Abdelzaher H, Saleh BM, Ismail HA, Hafiz M, Gabal MA, Mahmoud M, Hashish S, Gawad RMA, Gharieb RY, Abdelnaser A. COVID-19 Genetic and Environmental Risk Factors: A Look at the Evidence. Front Pharmacol 2020; 11: 579415. Almubaid Z, Al-Mubaid H. Analysis and comparison of genetic variants and mutations of the novel coronavirus SARS-CoV-2. Gene Rep 2021; 23: 101064. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr 2020; 14: 247-250. Borrelli MP, Buora A, Scrivere P, Sponza M, Frigatti P. Arterial Thrombotic Sequalae After Covid-19: Mind the Gap. Ann Vasc Surg 2021; 75: 128-135. Chanda A. COVID-19 in India: transmission dynamics, epidemiological characteristics, testing, recovery and effect of weather. Epidemiol Infect 2020; 148: e182. COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature 2021; 600: 472-477. Davies NG, Barnard RC, Jarvis CI, Kucharski AJ, Munday J, Pearson CA, Russell TW, Tully DC, Abbott S, Gimma A, Waites W. Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. MedRxiv. 2020 Jan 1. Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, Sotomayor-Gonzand;aacute;lez A, Glasner DR, Reyes KR, Gliwa AS, Reddy NP, Sanchez San Martin C, Federman S, Cheng J, Balcerek J, Taylor J, Streithorst JA, Miller S, Sreekumar B, Chen PY, Schulze-Gahmen U, Taha TY, Hayashi JM, Simoneau CR, Kumar GR, McMahon S, Lidsky PV, Xiao Y, Hemarajata P, Green NM, Espinosa A, Kath C, Haw M, Bell J, Hacker JK, Hanson C, Wadford DA, Anaya C, Ferguson D, Frankino PA, Shivram H, Lareau LF, Wyman SK, Ott M, Andino R, Chiu CY. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell 2021; 184: 3426-3437.e8. Dhakal BP, Sweitzer NK, Indik JH, Acharya D, William P. SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. Heart Lung Circ 2020; 29: 973-987. Di Giacomo S, Mercatelli D, Rakhimov A, Giorgi FM. Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K. J Med Virol 2021; 93: 5638-5643. Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH, Hauser BM, Feldman J, Pavlovic MN, Gregory DJ, Poznansky MC, Sigal A, Schmidt AG, Iafrate AJ, Naranbhai V, Balazs AB. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 2021; 184: 2372-2383.e9. Gomes C. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). Brazilian Journal of Implantology and Health Sciences 2020; 2(3). Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, Haagmans BL, Lauber C, Leontovich AM, Neuman BW, Penzar D. Severe acute respiratory syndrome-related coronavirus: The species and its viruses–a statement of the Coronavirus Study Group. BioRxiv 2020. Gravagnuolo AM, Faqih L, Cronshaw C, Wynn J, Klapper P, Wigglesworth M. High throughput diagnostics and dynamic risk assessment of SARS-CoV-2 variants of concern. EBioMedicine 2021; 70: 103540. He X, Hong W, Pan X, Lu G, Wei X. SARS-CoV-2 Omicron variant: Characteristics and prevention. MedComm (2020) 2021; 2: 838-845. Herrera NG, Morano NC, Celikgil A, Georgiev GI, Malonis RJ, Lee JH, Tong K, Vergnolle O, Massimi AB, Yen LY, Noble AJ, Kopylov M, Bonanno JB, Garrett-Thomson SC, Hayes DB, Bortz RH 3rd, Wirchnianski AS, Florez C, Laudermilch E, Haslwanter D, Fels JM, Dieterle ME, Jangra RK, Barnhill J, Mengotto A, Kimmel D, Daily JP, Pirofski LA, Chandran K, Brenowitz M, Garforth SJ, Eng ET, Lai JR, Almo SC. Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis. ACS Omega 2020; 6: 85-102. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020a; 395: 497-506. Huang X, Wei F, Hu L, Wen L, Chen K. Epidemiology and Clinical Characteristics of COVID-19. Arch Iran Med 2020b; 23: 268-271. Islam MA, Kundu S, Alam SS, Hossan T, Kamal MA, Hassan R. Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 17515 patients. PLoS One 2021; 16: e0249788. Jangra S, Ye C, Rathnasinghe R, Stadlbauer D; Personalized Virology Initiative study group, Krammer F, Simon V, Martinez-Sobrido L, Garcand;iacute;a-Sastre A, Schotsaert M. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe 2021; 2: e283-e284. Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ 2020; 368: m1198. Kandeel M, Mohamed MEM, Abd El-Lateef HM, Venugopala KN, El-Beltagi HS. Omicron variant genome evolution and phylogenetics. J Med Virol 2022; 94: 1627-1632. Kaviani M, Keshtkar S, Soleimanian S, Sarvestani FS, Azarpira N, Pakbaz S. Susceptibility to Metabolic Diseases in COVID-19: To be or not to be an Issue. Front Mol Biosci 2022; 9. Laha S, Chakraborty J, Das S, Manna SK, Biswas S, Chatterjee R. Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission. Infect Genet Evol 2020; 85: 104445. Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta 2020; 508: 254-266. Mahase E. Delta variant: What is happening with transmission, hospital admissions, and restrictions? BMJ 2021; 373: n1513. Makoni M. South Africa responds to new SARS-CoV-2 variant. Lancet 2021; 397: 267. Mathavan S, Kumar S. Evaluation of the effect of D614G, N501Y and S477N mutation in SARS-CoV-2 through computational approach, 2020. Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. J Microbiol Immunol Infect 2021; 54: 159-163. Nartikoeva MI, Takoeva EA. Diabetes and Metabolic Syndrome--Risk Factors for Covid-19 (literature review). Journal of International Dental and; Medical Research 2021; 14(4). Naveca FG, Nascimento V, de Souza VC, Corado AL, Nascimento F, Silva G, Costa and;Aacute;, Duarte D, Pessoa K, Mejand;iacute;a M, Brandand;atilde;o MJ, Jesus M, Gonand;ccedil;alves L, da Costa CF, Sampaio V, Barros D, Silva M, Mattos T, Pontes G, Abdalla L, Santos JH, Arantes I, Dezordi FZ, Siqueira MM, Wallau GL, Resende PC, Delatorre E, Grand;auml;f T, Bello G. COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence. Nat Med 2021; 27: 1230-1238. and;Ouml;zkand;ouml;se F, Yavuz M, Senel MT, Habbireeh R. Fractional order modelling of omicron SARS-CoV-2 variant containing heart attack effect using real data from the United Kingdom. Chaos Solitons Fractals 2022; 157: 111954. Patil S, Jagtap P, Kasabe B, Shah U, Sanjeev T, Divekar G, Korabu K, Shelkande S, Shinde P, Zakiuddin S, Vipat V. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India, 2021. Pitek AS, Wen AM, Shukla S, Steinmetz NF. The Protein Corona of Plant Virus Nanoparticles Influences their Dispersion Properties, Cellular Interactions, and In Vivo Fates. Small 2016; 12: 1758-1769. Rashedi J, Mahdavi Poor B, Asgharzadeh V, Pourostadi M, Samadi Kafil H, Vegari A, Tayebi-Khosroshahi H, Asgharzadeh M. Risk Factors for COVID-19. Infez Med 2020; 28: 469-474. Razeghian-Jahromi I, Zibaeenezhad MJ, Karimi Akhormeh A, Dara M. Expression ratio of circular to linear ANRIL in hypertensive patients with coronary artery disease. Sci Rep 2022; 12: 1802. Rouaud F, Mand;eacute;an I, Citi S. The ACE2 Receptor for Coronavirus Entry Is Localized at Apical Cell-Cell Junctions of Epithelial Cells. Cells 2022; 11: 627. Saito A, Suzuki R, Maemura T, Nasser H, Uriu K, Kosugi Y, Shirakawa K, Sadamasu K, Kimura I, Ito J, Wu J. SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion, 2021. Souza PFN, Mesquita FP, Amaral JL, Landim PGC, Lima KRP, Costa MB, Farias IR, Beland;eacute;m MO, Pinto YO, Moreira HHT, Magalhaes ICL, Castelo-Branco DSCM, Montenegro RC, de Andrade CR. The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape. Int J Biol Macromol 2022; 208: 105-125. Spychalski P, Blazynska-Spychalska A, Kobiela J. Estimating case fatality rates of COVID-19. Lancet Infect Dis 2020; 20: 774-775. Sriram K, Insel E, Loomba R. What is the ACE2 receptor, how is it connected to coronavirus and why might it be key to treating COVID-19? The experts explain. The Conversation 2020; 12. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh D, Pillay S, San EJ, Msomi N, Mlisana K. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. MedRxiv 2020 Jan 1. Tian F, Tong B, Sun L, Shi S, Zheng B, Wang Z, Dong X, Zheng P. N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2. Elife 2021; 10: e69091. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417-1418. Verghese M, Jiang B, Iwai N, Mar M, Sahoo MK, Yamamoto F, Mfuh KO, Miller J, Wang H, Zehnder J, Pinsky BA. A SARS-CoV-2 Variant with L452R and E484Q Neutralization Resistance Mutations. J Clin Microbiol 2021; 59: e0074121. Wang H, Li X, Li T, Zhang S, Wang L, Wu X, Liu J. The genetic sequence, origin, and diagnosis of SARS-CoV-2. Eur J Clin Microbiol Infect Dis 2020; 39: 1629-1635. Weckbach LT, Curta A, Bieber S, Kraechan A, Brado J, Hellmuth JC, Muenchhoff M, Scherer C, Schroeder I, Irlbeck M, Maurus S, Ricke J, Klingel K, Kand;auml;and;auml;b S, Orban M, Massberg S, Hausleiter J, Grabmaier U. Myocardial Inflammation and Dysfunction in COVID-19-Associated Myocardial Injury. Circ Cardiovasc Imaging 2021; 14: e012220. Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F, Rutkowska M, Hoffmann HH, Michailidis E, Gaebler C, Agudelo M, Cho A, Wang Z, Gazumyan A, Cipolla M, Luchsinger L, Hillyer CD, Caskey M, Robbiani DF, Rice CM, Nussenzweig MC, Hatziioannou T, Bieniasz PD. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife 2020; 9: e61312. Xiong X, Qu K, Ciazynska KA, Hosmillo M, Carter AP, Ebrahimi S, Ke Z, Scheres SHW, Bergamaschi L, Grice GL, Zhang Y; CITIID-NIHR COVID-19 BioResource Collaboration, Nathan JA, Baker S, James LC, Baxendale HE, Goodfellow I, Doffinger R, Briggs JAG. A thermostable, closed SARS-CoV-2 spike protein trimer. Nat Struct Mol Biol 2020; 27: 934-941. Zhang L, Jackson CB, Mou H, Ojha A, Rangarajan ES, Izard T, Farzan M, Choe H. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. bioRxiv 2020 Jun 12:2020.06.12.148726. Zhao H, Lu L, Peng Z, Chen LL, Meng X, Zhang C, Ip JD, Chan WM, Chu AW, Chan KH, Jin DY, Chen H, Yuen KY, To KK. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect 2022; 11: 277-283.</References> </References> </Journal> </Article> </ArticleSet>